Hormone therapy with tamoxifen reduces plasma levels of NT-B-type natriuretic peptide but does not change ventricular ejection fraction after chemotherapy in women with breast cancer

Hormone therapy with tamoxifen reduces plasma levels of NT-B-type natriuretic peptide but does not change ventricular ejection fraction after chemotherapy in women with breast cancer

The objective of this study was to evaluate the effect of tamoxifen on the plasma concentration of NT-pro-B-type natriuretic peptide (NT-proBNP) in women undergoing chemotherapy for breast cancer and to correlate changes in NT-proBNP with the left ventricular ejection fraction (LVEF). Over a period...

Full description

Saved in:
Bibliographic Details
Published in:Brazilian journal of medical and biological research Vol. 48; no. 2; pp. 154 - 160
Main Authors: Silva, F B, Romero, W G, Carvalho, A L R, Borgo, M V, Amorim, M H C, Gouvea, S A, Abreu, G R
Format: Journal Article
Language:English
Published: Brazil Associacao Brasileira de Divulgacao Cientifica (ABDC) 01-02-2015
Associação Brasileira de Divulgação Científica
Subjects:
Adjuvant chemotherapy
Adult
Analysis
Analysis of Variance
Antineoplastic Agents, Hormonal - therapeutic use
BIOLOGY
Biomarkers - blood
Breast cancer
Breast Neoplasms - drug therapy
Cancer
Cardiovascular risk profile
Care and treatment
Chemotherapy
Chemotherapy, Adjuvant
Clinical Investigation
Cyclophosphamide - therapeutic use
Dosage and administration
Doxorubicin - therapeutic use
Echocardiography
Ecocardiography
Female
Fluorouracil - therapeutic use
Follow-Up Studies
Health aspects
Hormone therapy
Humans
MEDICINE, RESEARCH & EXPERIMENTAL
Middle Aged
Natriuretic Peptide, Brain - blood
Natriuretic peptides
NT-B-proBNP
Paclitaxel - therapeutic use
Peptide Fragments - blood
Statistics as Topic
Stroke Volume - drug effects
Tamoxifen
Tamoxifen - therapeutic use
Women
Adjuvant chemotherapy
Ecocardiography
Hormone therapy
NT-B-proBNP
Cardiovascular risk profile
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this study was to evaluate the effect of tamoxifen on the plasma concentration of NT-pro-B-type natriuretic peptide (NT-proBNP) in women undergoing chemotherapy for breast cancer and to correlate changes in NT-proBNP with the left ventricular ejection fraction (LVEF). Over a period of 12 months, we followed 60 women with a diagnosis of breast cancer. The patients were separated into a group that received only chemotherapy (n=23), a group that received chemotherapy + tamoxifen (n=21), and a group that received only tamoxifen (n=16). Plasma levels of NT-proBNP were assessed at 0 (T0), 6 (T6), and 12 (T12) months of treatment, and echocardiography data were assessed at T0 and T12. Plasma NT-proBNP levels were increased in the chemotherapy-only group at T6 and T12, whereas elevated NT-proBNP levels were only found at T6 in the chemotherapy + tamoxifen group. At T12, the chemotherapy + tamoxifen group exhibited a significant reduction in the peptide to levels similar to the group that received tamoxifen alone. The chemotherapy-only group exhibited a significant decrease in LVEF at T12, whereas the chemotherapy + tamoxifen and tamoxifen-only groups maintained levels similar to those at the beginning of treatment. Treatment with tamoxifen for 6 months after chemotherapy significantly reduced the plasma levels of NT-proBNP and did not change LVEF in women with breast cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0100-879X
1414-431X
1414-431X
DOI:10.1590/1414-431X20144189